Botox is more than just a blockbuster product these days. It's a lure for would-be Allergan ($AGN) buyer Valeant Pharmaceuticals ($VRX). And it's one of the few drugs that Valeant thinks is worth some significant R&D investment. But would that frugal company spend enough to keep pumping out new indications--and new marketing avenues? Report